A study presented at the APASL 2024 conference reported no significant differences in overall HBsAg decline rate or HBsAg seroclearance between CHB patients with and without fatty liver after 48 weeks of Peg-IFN treatment, which is consistent with our results. This evidence concerns the gene IFNA1 and fatty liver disease.